We are live on ! Find out more
EVMN icon

Evommune

105 hedge funds and large institutions have $463M invested in Evommune in 2026 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 36 increasing their positions, 13 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

177% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 13

141% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 17

34% more capital inflows, than outflows

Capital inflows: $204M | Capital outflows: $151M

25% more funds holding

Funds holding: 84 → 105 (+21)

0.03% more ownership

Funds ownership: 96% → 96.03% (+0.03%)

29% less funds holding in top 10

Funds holding in top 10: 7 → 5 (-2)

29% less call options, than puts

Call options by funds: $5.91M | Put options by funds: $8.32M

Holders
105
Holders Change
+21
Holders Change %
+25%
% of All Funds
1.25%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.06%
New
41
Increased
36
Reduced
13
Closed
17
Calls
$5.91​M
Puts
$8.32​M
Net Calls
-⁠$2.41​M
Net Calls Change
-⁠$2.41​M

EVMN Hedge Fund Activity: Q2 2026 in Review

105 of the 8,395 institutional investors tracked by Wall St. Rank reported a position in Evommune (EVMN) for Q2 2026, worth a combined $463M — down 42% from $793M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new EVMN positions and 17 closed out — a net gain of 24 holders — while 36 added to existing stakes and 13 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $32.5M. The largest seller was MPM BioImpact, exiting entirely with an estimated $33.5M sold.

  • 105 institutional investors held Evommune (EVMN) as of Q2 2026, up from 84 in Q1 2026.
  • Funds reported $463M of Evommune stock for Q2 2026, down 42% quarter-over-quarter.
  • 41 funds opened new Evommune positions in Q2 2026 and 17 closed out, a net change of +24 holders.
  • The largest Evommune buyer in Q2 2026 was Point72 Asset Management, an estimated $32.5M added.
  • The largest Evommune seller in Q2 2026 was MPM BioImpact, an estimated $33.5M sold.

Based on aggregated 13F filings for Q2 2026.